Showing 5391-5400 of 8159 results for "".
- L'Oreal International Extends Deadline for Social Responsibility in Dermatology Awardshttps://practicaldermatology.com/news/loreal-international-extends-deadline-for-social-responsibility-in-dermatology-awards/2458996/L’Oréal announced today the extension of the closing date of its International Awards for Social Responsibility in Dermatology to April 15th 2015. Patients with dermatological conditions may frequently face discrimination and feel socially excluded,
- Promius Pharma, LLC to Market, Distribute Trianex 0.05%https://practicaldermatology.com/news/promius-pharma-llc-to-market-distribute-trianex-005/2458997/Promius Pharma, LLC, has acquired the rights to market and distribute Trianex® 0.05% (Triamcinolone Acetonide Ointment, USP) in the United States from CMP Pharma, Inc. Trianex Ointment, a mid-potency corticosteroid, is notable for its white formulation that has the look and feel of
- Novel Anti-Biofilm AQUACEL™ Ag+ Dressing Demonstrates Positive Results in Hard-to-Heal Woundshttps://practicaldermatology.com/news/novel-anti-biofilm-aquacel-ag-dressing-demonstrates-positive-results-in-hard-to-heal-wounds/2458998/A new, multi-country, clinical evaluation study showed that AQUACEL™ Ag+ wound dressing demonstrated positive results in wounds, including those compromised by biofilm and/or infection. AQUACEL™ Ag+ dressings are designed to disrupt biofilm and kill infection-
- FDA Clears New 532 nm Laser Delivery System for PicoSure from Cynosurehttps://practicaldermatology.com/news/fda-clears-new-532-nm-laser-delivery-system-for-picosure-from-cynosure/2459001/Cynosure, Inc. received FDA 510(k) clearance of its new 532 nm Laser Delivery System for PicoSure®, creating a powerful, dual-wavelength laser system for removing tattoos of all colors in fewer treatments. PicoSure is widely recognized for its technology
- Investigational Atopic Dermatitis Cream Disappoints in Phase II Trialhttps://practicaldermatology.com/news/investigational-atopic-dermatitis-cream-disappoints-in-phase-ii-trial/2459003/Results from a phase II trial do not bode well for the future of the investigational atopic dermatitis cream MRX-6. The double-blind, parallel-group, vehicle-controlled study evaluated the safety and efficacy of MRX-6 cream 2% among 73 children suffering from mild-to-moderate atopic dermatitis. P
- Actavis Divests Rights to Doryx to Mayne Pharmahttps://practicaldermatology.com/news/actavis-divests-rights-to-doryx-to-mayne-pharma/2459007/Actavis will divest the US rights to its oral acne treatment brand Doryx and other assets related to the acne brand to Mayne Pharma, in a deal worth $50 million. Actavis currently holds the license for the distribution of Doryx in the US under a partnership between Warner Chilcott Plc, which was
- Pfizer Announces FDA Acceptance For Review of Supplemental New Drug Application for Oral Xeljanz For Plaque Psoriasishttps://practicaldermatology.com/news/pfizer-announces-fda-acceptance-for-review-of-supplemental-new-drug-application-for-oral-xeljanz-for-plaque-psoriasis/2459011/The FDA accepted for review Pfizer Inc.’s supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate) 5mg and 10mg tablets, a Janus kinase (JAK) inhibitor, the first in a new class of oral medicines being investigated for the treatment of adult patients with moderate to sever
- New App for Clinical Skin Cancer Diagnosis Launches on World Cancer Day 2015; Physician Input Soughthttps://practicaldermatology.com/news/new-app-for-clinical-skin-cancer-diagnosis-launches-on-world-cancer-day-2015-physician-input-sought/2459012/On World Cancer Day 2015, general practitioners, physicians, and dermatologists in the United States, United Kingdom and Australia were asked for their feedback during the advanced trial phase of a new, free app that has the potential to play a role in the clinical detection of skin cancer.
- Halozyme Appoints Jean-Pierre Bizzari, MD to Board Of Directorshttps://practicaldermatology.com/news/halozyme-appoints-jean-pierre-bizzari-md-to-board-of-directors/2459021/Halozyme Therapeutics, Inc. appointed of Jean-Pierre Bizzari, MD to its Board of Directors. Dr. Bizzari brings extensive experience in oncology drug development. "I am delighted to welcome Jean-Pierre to our Board of Directors," said Dr. Helen Torley, President and Chief Executi
- derma e Launches Firming and Deep Wrinkle Productshttps://practicaldermatology.com/news/derma-e-launches-firming-and-deep-wrinkle-products/2459020/derma e® launched its new Firming DMAE Eye Lift and Deep Wrinkle Peptide Moisturizer SPF 30. “derma e® is raising the bar for natural skin care performance with the launch of these two new products,” says Jennifer Norman, Vice President of Marketing for derma e®. &